PRP Response Prediction Using Genetic Polymorphisms and Age

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods cannot reliably predict a subject's response to Platelet Rich Plasma (PRP) treatment, which is influenced by individual genetic and environmental factors, limiting the effectiveness of PRP therapy for musculoskeletal pathologies.

Innovation Solution

An in vitro method utilizing genetic polymorphisms of GH1, SOD2, UCP2, GCKR, IGFR-1, VEGFR2, and ADRB2 genes, combined with the environmental variable 'age', to calculate a subject's probability of responding positively to PRP treatment through an algorithm that considers both genetic and environmental variables.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PRP treatment is applied to patients with musculoskeletal pathologies, then regenerative effects and symptom relief are achieved, but individual response variability limits treatment effectiveness

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidindividual response variability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies preliminary action by performing genetic polymorphism analysis and algorithmic probability calculation before PRP treatment to identify patients likely to respond positively. This pre-screening approach allows clinicians to select appropriate candidates in advance, avoiding ineffective treatments and improving overall treatment reliability.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the parameter of patient selection from clinical observation alone to a quantitative probability score based on genetic polymorphisms. By analyzing specific genetic variants and calculating a probability value using a proprietary algorithm, the treatment approach adapts to individual genetic characteristics, thereby improving response reliability.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If genetic polymorphism analysis is performed to predict PRP response, then prediction accuracy is improved, but test complexity and cost increase

Engineering Contradiction:

Improveresponse prediction accuracyVSAvoidgenetic testing complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the genetic analysis into specific polymorphism loci associated with PRP response, rather than performing whole-genome sequencing. By focusing on predetermined genetic markers and using targeted genotyping methods, the system achieves high prediction accuracy while maintaining relatively simple and cost-effective testing procedures.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentEP4685242A1Method for obtaining useful data for the prediction of a subject's response to platelet-rich plasma treatment

Publication Date: 2026.01.28 SANTXA RES S L U

Figure 1
Figure 2
Figure 3

AI summary

The present invention relates to an in vitro method of obtaining useful data for estimating a subject's probability of responding positively to Platelet Rich Plasma (PRP) treatment, comprising the analysis of a series of genetic polymorphisms together with an environmental variable characteristic of the subject. The present invention also relates to a kit comprising the means necessary to detect the genetic polymorphisms and the use of said kit in the aforementioned in vitro method.